Last updated: September 8, 2026
Melphalan is a mature alkylating agent with limited branded-drug growth but continuing clinical demand in multiple myeloma, conditioning before autologous hematopoietic stem-cell transplantation, and selected ovarian-cancer treatment. The conventional molecule has largely generic economics. The main commercial opportunity has shifted from the active ingredient to differentiated formulations, hospital supply reliability, sterile manufacturing, and specialty-distribution access.
The market has two distinct segments:
- Conventional melphalan, including oral melphalan tablets and injectable melphalan hydrochloride.
- Melphalan-based differentiated products, particularly Evomela, an intravenous formulation developed to improve preparation and administration.
Melphalan flufenamide, marketed as Pepaxto, is a separate chemical entity and should not be included in conventional melphalan revenue or patent analysis.
What is melphalan used for and how large is the market?
Melphalan is a nitrogen mustard alkylating agent that damages DNA and inhibits malignant-cell proliferation. Its primary current use is in multiple myeloma and transplant conditioning.
| Product or presentation |
Principal use |
Commercial status |
| Oral melphalan tablets |
Multiple myeloma; selected ovarian cancer treatment |
Generic and legacy-brand market |
| Melphalan hydrochloride injection |
Multiple myeloma and ovarian cancer; palliative or combination treatment |
Generic injectable market |
| Evomela |
Conditioning before autologous stem-cell transplantation in multiple myeloma; selected multiple-myeloma treatment |
Branded specialty injectable |
| Pepaxto, melphalan flufenamide |
Relapsed or refractory multiple myeloma |
Separate molecule and regulatory history |
FDA labeling identifies melphalan injection for use in multiple myeloma and ovarian cancer, while oral melphalan has historically been used for multiple myeloma and ovarian cancer under the Alkeran brand and generic equivalents (FDA, 2023a; FDA, 2023b).
The conventional melphalan market is difficult to size from public company filings because generic tablets and injectables are sold by several suppliers and most manufacturers do not report product-level revenue. U.S. sales are likely concentrated in hospital injectables and specialty-distribution channels rather than retail pharmacy volume.
How has melphalan’s financial trajectory developed?
Melphalan’s financial trajectory has followed the standard pattern for an old oncology molecule: high historical value, post-generic price compression, and renewed branded pricing for a differentiated formulation.
Historical branded period
Alkeran was developed and commercialized decades before the modern Hatch-Waxman system. Its original commercial value came from clinical adoption in multiple myeloma and ovarian cancer. The molecule has no remaining composition-of-matter exclusivity in the United States.
Generic erosion
Generic melphalan tablets and injectable products reduced the value of the original brand. The product remains commercially relevant because demand is tied to established treatment protocols, but unit economics are constrained by generic competition and hospital purchasing pressure.
Evomela expansion
Spectrum Pharmaceuticals launched Evomela after FDA approval in 2016. The product used a reformulated melphalan hydrochloride presentation intended to improve preparation and reduce handling problems associated with conventional injectable melphalan. Evomela entered a specialty market in which transplant centers can value predictable reconstitution, storage, and administration characteristics.
Spectrum later became part of the Acrotech Biopharma portfolio. Acrotech is privately held, and it does not provide the same level of product-specific quarterly revenue disclosure as a public pharmaceutical company. Evomela revenue is therefore not independently visible in current public filings.
| Period |
Financial interpretation |
| Before generic entry |
Brand-led revenue from Alkeran |
| After generic entry |
Lower pricing and fragmented supplier economics |
| 2016 onward |
Premium opportunity for Evomela’s differentiated injectable formulation |
| Current market |
Mature conventional melphalan plus specialty injectable economics |
| Medium term |
Stable clinical demand, but limited volume growth and persistent price pressure |
Public financial records from Spectrum show that Evomela contributed to the company’s commercial portfolio after approval, but reported results were generally presented alongside other products rather than as a complete standalone revenue series (Spectrum Pharmaceuticals, 2017, 2018).
What is the current FDA regulatory status of melphalan?
Conventional melphalan has long-standing FDA approval. The regulatory barriers are lower for generic products than for new chemical entities, but sterile manufacturing and drug-shortage risk remain important.
Conventional melphalan
FDA-approved conventional presentations include:
- Oral melphalan tablets.
- Melphalan hydrochloride for injection.
- Products labeled for multiple myeloma and ovarian cancer, subject to the specific approved labeling of each product.
Evomela
FDA approved Evomela in 2016 under NDA 208162. The product is melphalan hydrochloride for injection and is approved for:
- Conditioning treatment before autologous stem-cell transplantation in patients with multiple myeloma.
- Palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate.
Evomela’s approval was based on a new formulation and manufacturing approach rather than a new active ingredient. The product therefore did not receive the five-year new chemical entity exclusivity available to an innovative molecular entity (FDA, 2016).
Pepaxto distinction
Pepaxto contains melphalan flufenamide, not melphalan. FDA granted accelerated approval for relapsed or refractory multiple myeloma in 2021. FDA later withdrew the approval after confirmatory evidence raised concerns regarding overall survival and benefit-risk balance (FDA, 2024). Pepaxto’s regulatory history affects the broader melphalan-derived competitive landscape but does not alter the approval status of conventional melphalan or Evomela.
What is the Orange Book status of melphalan?
The Orange Book contains product-level listings for approved melphalan products, including legacy and generic presentations. Orange Book status must be assessed by NDA, dosage form, strength, and manufacturer because the listing status of oral and injectable products is not identical (FDA, 2024a).
The practical Orange Book conclusions are:
- Conventional melphalan has no meaningful remaining compound patent barrier.
- Generic competition is legally available through ANDA pathways.
- Formulation-specific patents may affect branded injectable products.
- Method-of-use listings are narrower than composition-of-matter protection and generally have limited ability to preserve the entire market.
- An Orange Book patent listing does not prevent an ANDA applicant from filing a Paragraph IV certification.
Because melphalan is an old active ingredient, the principal patent issue is formulation and manufacturing protection rather than molecule ownership.
What patents protect melphalan and Evomela?
The conventional melphalan patent estate is weak at the active-ingredient level and stronger, where applicable, at the formulation level.
Composition-of-matter patents
The original melphalan compound patents have expired. No U.S. generic entrant faces a live composition-of-matter patent covering melphalan itself.
Formulation patents
Evomela was developed around a formulation intended to improve the stability and handling of melphalan hydrochloride for injection. Formulation claims can cover combinations of:
- Melphalan hydrochloride.
- Specific solvents or excipients.
- pH ranges.
- Reconstitution procedures.
- Stability characteristics.
- Lyophilized or ready-to-use presentations.
- Storage and administration conditions.
The commercial value of these claims depends on claim scope, Orange Book listing, patent-term adjustment, pediatric extensions, and whether an ANDA applicant can design around the protected formulation.
Manufacturing and process protection
Manufacturing know-how may be more important than publicly visible patents. Sterile production of a cytotoxic injectable requires validated containment, aseptic processing, specialized packaging, and reliable supply of active pharmaceutical ingredient. These factors can delay or discourage entry even when the legal patent barrier is limited.
Patent-strength assessment
| Protection layer |
Current strength |
Commercial effect |
| Melphalan molecule |
Very weak or expired |
Does not block generic entry |
| Oral formulation |
Weak |
Generic competition is established |
| Injectable formulation |
Moderate where formulation patents remain enforceable |
Can support premium pricing |
| Manufacturing process |
Moderate operational barrier |
May limit reliable supply |
| Clinical-use patents |
Narrow |
Protect only specified treatment methods |
| Trade secrets and quality systems |
Moderate |
Important for sterile oncology products |
A formulation patent does not create the same defensibility as a new chemical entity patent. The product may retain a premium only if the formulation provides a clinically or operationally meaningful advantage and generic competitors cannot readily replicate it.
When does melphalan lose exclusivity?
Melphalan’s core exclusivity has already expired. The relevant question is not when the molecule loses exclusivity, but how long differentiated presentations can preserve branded share.
| Exclusivity category |
Status |
| Original compound patent |
Expired |
| Five-year NCE exclusivity |
Not applicable |
| Oral melphalan generic entry |
Established |
| Injectable melphalan generic entry |
Established or legally available |
| Evomela regulatory exclusivity |
Any original new-product exclusivity has expired |
| Formulation patents |
Must be evaluated patent by patent |
| Pediatric exclusivity |
No broad market-blocking protection identified for conventional melphalan |
The risk profile therefore changes from a cliff event to gradual erosion. A branded injectable can retain revenue after generic approval if hospitals value its preparation characteristics, supply reliability, or contracting position.
Which companies are challenging or competing with melphalan?
Competition comes from both direct melphalan suppliers and alternative multiple-myeloma regimens.
Direct product competitors
The competitive set includes:
- Acrotech Biopharma, through Evomela.
- Generic injectable manufacturers.
- Generic oral melphalan suppliers.
- Contract manufacturers and specialty distributors that supply hospital systems.
Public information is insufficient to assign a complete current market share by manufacturer because much of the market is privately held, distributed through wholesalers, or recorded at the portfolio level.
Therapeutic competitors
Melphalan competes indirectly with:
- High-dose chemotherapy regimens using alternative conditioning agents.
- Bortezomib-based induction and maintenance strategies.
- Lenalidomide and other immunomodulatory agents.
- Anti-CD38 antibodies such as daratumumab.
- Proteasome inhibitors such as carfilzomib.
- BCMA-directed therapies in relapsed multiple myeloma.
These agents do not generally replace melphalan in transplant-conditioning protocols. They compete for treatment budgets and influence the number of patients reaching transplant.
What generic entry risks exist for melphalan?
Generic entry risk is high for conventional melphalan and moderate for differentiated injectable products.
Oral melphalan
Oral melphalan has the highest generic risk because:
- The active ingredient is old.
- Clinical use is well established.
- The formulation is relatively straightforward.
- Brand loyalty is limited.
- Prescribing is usually based on molecule and dose rather than a proprietary delivery system.
Injectable melphalan
Injectable melphalan has more complex entry economics because:
- Cytotoxic handling raises manufacturing requirements.
- Sterile injectable capacity is constrained.
- Hospital buyers prioritize supply continuity.
- Formulation patents may remain relevant.
- A generic must demonstrate pharmaceutical equivalence and comply with injectable manufacturing standards.
The commercial threat is therefore not limited to the number of approved ANDAs. A small number of dependable suppliers can exert substantial pricing pressure, while manufacturing failures can temporarily increase the value of an incumbent product.
What patent litigation and Paragraph IV activity affect melphalan?
Melphalan has a lower litigation profile than newer oncology products. The main reason is that the underlying molecule is old and generic availability is established.
Potential litigation would most likely involve:
- Formulation patents associated with Evomela.
- ANDA Paragraph IV challenges.
- Patent-listing disputes.
- Claim construction for reconstitution or stability limitations.
- Commercial-launch disputes after FDA approval of a competing injectable.
A Paragraph IV certification would challenge the validity, enforceability, or infringement of a listed patent. If the NDA holder sued within the statutory period, FDA approval could be stayed for up to 30 months, subject to statutory exceptions and court developments (Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355).
No broad, molecule-level Paragraph IV barrier should be assumed for conventional melphalan. The decisive question for a branded injectable is whether the relevant formulation patents are listed, enforceable, and difficult to design around.
How does melphalan compare with melphalan flufenamide?
| Attribute |
Melphalan |
Melphalan flufenamide |
| Active ingredient |
Melphalan |
Melphalan flufenamide |
| Product examples |
Alkeran, generic melphalan, Evomela |
Pepaxto |
| Molecular status |
Mature cytotoxic agent |
Newer melphalan-derived compound |
| Main market |
Multiple myeloma; transplant conditioning; ovarian cancer |
Relapsed or refractory multiple myeloma |
| Patent position |
Core patents expired; formulation protection may remain |
Newer composition and use patents |
| FDA history |
Long-standing approvals |
Accelerated approval followed by withdrawal |
| Pricing model |
Generic or specialty formulation |
Branded specialty oncology |
| Current commercial risk |
Generic erosion and supply competition |
Regulatory withdrawal and clinical-risk exposure |
This distinction is material in market models. Revenue attributed to Pepaxto should not be added to the conventional melphalan market.
What is the geographic coverage and manufacturing risk?
Melphalan is sold internationally through generic and branded channels. Geographic economics vary by reimbursement system, procurement structure, and local generic approval.
The United States has the strongest branded opportunity for Evomela because specialty oncology reimbursement can support a premium over conventional injectable melphalan. European and other regulated markets generally impose greater price controls and centralized procurement pressure.
Manufacturing barriers include:
- High-potency cytotoxic containment.
- Aseptic filling and lyophilization.
- Stability and reconstitution validation.
- Specialized packaging.
- Active pharmaceutical ingredient supply.
- Compliance with FDA and international good manufacturing practice standards.
These constraints can create episodic shortages. Shortages may increase near-term sales for available suppliers but can also trigger hospital substitution and government procurement intervention.
What is the outlook for melphalan revenue?
The base-case outlook is stable to modestly declining for conventional melphalan and more resilient for differentiated injectable products.
| Revenue driver |
Expected direction |
| Oral generic pricing |
Downward |
| Injectable generic volume |
Stable to modest growth |
| Transplant-conditioning demand |
Stable, linked to multiple-myeloma incidence and transplant rates |
| Evomela price premium |
Vulnerable to generic formulation entry |
| Hospital shortage events |
Volatile, potentially favorable for available suppliers |
| New indications |
Limited |
| Multiple-myeloma treatment expansion |
Positive for utilization, but offset by substitution and generic pricing |
Melphalan is unlikely to become a high-growth pharmaceutical asset. Its financial value lies in recurring institutional demand, regulatory continuity, and the ability to preserve share through formulation differentiation and dependable supply.
Key Takeaways
- Melphalan is a mature oncology molecule with expired core patent protection.
- Generic competition dominates oral melphalan economics.
- Injectable products have greater commercial resilience because sterile manufacturing and hospital supply reliability matter.
- Evomela is the main differentiated melphalan product, but its commercial protection depends on formulation patents and execution rather than molecule exclusivity.
- Melphalan flufenamide, or Pepaxto, is a separate drug and should be analyzed separately.
- No broad molecule-level patent barrier should prevent conventional generic entry.
- The principal risks are formulation design-arounds, generic injectable launches, price compression, and hospital procurement changes.
- The financial outlook is stable rather than growth-oriented, with revenue concentrated in specialty injectable and institutional channels.
FAQs
Is melphalan still under patent?
The original melphalan molecule is no longer protected by an active U.S. composition-of-matter patent. Certain formulation, process, or use claims may remain relevant for branded injectable products.
Is Evomela a generic form of melphalan?
Evomela contains melphalan hydrochloride, but it is a branded formulation with product-specific manufacturing and formulation characteristics. It is not simply the same commercial presentation as every generic melphalan injection.
Can generic manufacturers launch melphalan injection?
Yes. Generic launch depends on FDA approval, applicable Orange Book patents, Paragraph IV certification, litigation, and the manufacturer’s ability to meet sterile cytotoxic production requirements.
Does multiple-myeloma growth increase melphalan sales?
Multiple-myeloma incidence and treatment expansion support demand, but the effect is moderated by generic pricing, changes in transplant utilization, and competing therapies used before and after transplantation.
Is Pepaxto included in the melphalan market?
No. Pepaxto contains melphalan flufenamide, a distinct active ingredient. Its regulatory and patent history should not be combined with conventional melphalan products.
References
- Acrotech Biopharma. (n.d.). Evomela product information.
- Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355.
- U.S. Food and Drug Administration. (2016). FDA approves Evomela for multiple myeloma.
- U.S. Food and Drug Administration. (2023a). Melphalan hydrochloride for injection prescribing information.
- U.S. Food and Drug Administration. (2023b). Melphalan tablets prescribing information.
- U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- U.S. Food and Drug Administration. (2024b). Pepaxto safety communications and approval status.
- Spectrum Pharmaceuticals, Inc. (2017). Annual report on Form 10-K.
- Spectrum Pharmaceuticals, Inc. (2018). Annual report on Form 10-K.
